Whilst we have named antidepressant groups based on trajectory at a population level there is likely to be significant heterogeneity in individual circumstances, whereby individuals are not experiencing the group level dynamic, e.g. co-morbidities and interactions with anxiolytic and anti-psychotic treatments might be driving antidepressant trend rather than the disease worsening.
← all excerpts
Use of sequence analysis for classifying individual antidepressant trajectories to monitor population mental health.
1
—
—